OssDsign Management

Management criteria checks 2/4

OssDsign's CEO is Morten Henneveld, appointed in Sep 2020, has a tenure of 3.75 years. total yearly compensation is SEK7.94M, comprised of 54% salary and 46% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €165.22K. The average tenure of the management team and the board of directors is 3.6 years and 6.8 years respectively.

Key information

Morten Henneveld

Chief executive officer

kr7.9m

Total compensation

CEO salary percentage	54.0%
CEO tenure	3.8yrs
CEO ownership	0.2%
Management average tenure	3.6yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Morten Henneveld's remuneration changed compared to OssDsign's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-kr118m
Dec 31 2023	kr8m	kr4m	-kr130m
Sep 30 2023	n/a	n/a	-kr109m
Jun 30 2023	n/a	n/a	-kr95m
Mar 31 2023	n/a	n/a	-kr99m
Dec 31 2022	kr6m	kr4m	-kr99m
Sep 30 2022	n/a	n/a	-kr96m
Jun 30 2022	n/a	n/a	-kr93m
Mar 31 2022	n/a	n/a	-kr95m
Dec 31 2021	kr6m	kr6m	-kr94m
Sep 30 2021	n/a	n/a	-kr90m
Jun 30 2021	n/a	n/a	-kr92m
Mar 31 2021	n/a	n/a	-kr90m
Dec 31 2020	kr1m	kr1m	-kr85m

Compensation vs Market: Morten's total compensation ($USD754.90K) is above average for companies of similar size in the German market ($USD433.20K).

Compensation vs Earnings: Morten's compensation has increased whilst the company is unprofitable.

CEO

Morten Henneveld (48 yo)

3.8yrs

Tenure

kr7,939,000

Compensation

Mr. Morten Henneveld has been Chief Executive Officer at OssDsign AB (publ) since September 1, 2020. Mr. Henneveld serves as a Director at Sime Diagnostics Ltd., since October 2022. He is Senior Vice Presi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Morten Henneveld	Chief Executive Officer	3.8yrs	kr7.94m	0.20% SEK 165.2k
Håkan Engqvist	Co-Founder & Director	no data	kr150.00	0.23% SEK 185.1k
Anders Svensson	Chief Financial Officer	3.6yrs	no data	0.085% SEK 68.5k
Tom Buckland	Chief Technical Officer	less than a year	no data	no data
Melanie Marshall	Vice President of Clinical & Medical Affairs	2.4yrs	no data	no data
Eric Patermo	Vice President of Sales US	4.4yrs	no data	no data

3.6yrs

Average Tenure

52yo

Average Age

Experienced Management: 5J6's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Håkan Engqvist	Co-Founder & Director	8.4yrs	kr150.00	0.23% SEK 185.1k
Viktor Drvota	Independent Director	9.4yrs	no data	no data
Newton Aguiar	Independent Director	5.4yrs	kr250.00	0.10% SEK 82.5k
Anders Qvarnstrom	Independent Director	5.4yrs	kr250.00	0.057% SEK 45.6k
Simon Cartmell	Independent Chairman of the Board	8.2yrs	kr350.00	0.13% SEK 103.3k
Jill Schiaparelli	Independent Director	2yrs	kr250.00	no data

6.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 5J6's board of directors are considered experienced (6.8 years average tenure).

OssDsign Management

Management criteria checks 2/4

Key information

Recent management updates

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

OssDsign AB (publ), Annual General Meeting, May 21, 2024

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Insufficient new directors

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Recent updates

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share

Revenue misses expectations

OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.42

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.169392 million.

Earnings released

OssDsign AB (publ) Announces Chief Executive Officer Changes

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age